{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:10:15Z","timestamp":1784002215106,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2021,9,7]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">The objective was to evaluate predictive performance and optimal decision threshold of the Kryptor soluble fms\u2010like tyrosine kinase\u20101 (sFlt\u20101)\/placental growth factor (PlGF) ratio when implemented for routine management of women presenting with symptoms of preeclampsia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">Observational retrospective study of a cohort of 501 women with suspected preeclampsia after 20 weeks\u00a0of gestation. Women referred to maternity ward for observation of preeclampsia had an sFlt\u20101\/PlGF ratio test included in routine diagnostic workup. Maternal and offspring characteristic data included maternal risk factors, outcomes, delivery mode, and indication for suspected preeclampsia. Biochemical measurements to determine sFlt\u20101\/PlGF ratio were performed using the BRAHMS\/Kryptor sFlt\u20101\/PlGF ratio immunoassays. Results were analyzed by area under receiver\u2010operating characteristic curve. Preeclampsia occurred in 150 of 501 (30%) of symptomatic women with an sFlt\u20101\/PlGF ratio determined before the time of diagnosis. Area under receiver\u2010operating characteristic curve for diagnosis of early\u2010onset preeclampsia within 1 and 4 weeks was 0.98 (95% CI, 0.96\u20131.00) and 0.95 (95% CI, 0.92\u20130.98), respectively. For late\u2010onset preeclampsia, predictive performance within 1 and 4 weeks was lower: 0.90 (95% CI, 0.85\u20130.94) and 0.85 (95% CI, 0.80\u20130.90), respectively. The optimal single sFlt\u20101\/PlGF ratio threshold for all preeclampsia and late\u2010onset preeclampsia within 1 and 4 weeks was 66. The negative and positive predictive values for ruling out and ruling in developing preeclampsia within 1 week were 96% and 70%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">The Kryptor sFlt\u20101\/PlGF ratio is a useful clinical tool ruling out and in preeclampsia within 1 week. Prediction within 4 weeks is superior for early\u2010onset preeclampsia. A single decision threshold of 66 is indicated for use in clinical routine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.120.021376","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T09:06:59Z","timestamp":1630141619000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Decision Threshold for Kryptor sFlt\u20101\/PlGF Ratio in Women With Suspected Preeclampsia: Retrospective Study in a Routine Clinical Setting"],"prefix":"10.1161","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-2228","authenticated-orcid":false,"given":"Lise Lotte Torvin","family":"Andersen","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology Odense University Hospital Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Helt","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Odense University Hospital Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Odense University Hospital Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-590X","authenticated-orcid":false,"given":"Martin","family":"Overgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Research University of Southern Denmark Odense Denmark"},{"name":"Department of Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/214365"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000472"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0119-6"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2013.05.005"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60279-6"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.08.019"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1081\/PRG-120021060"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01113.2007"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.22.10705"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17189"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10182"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031884"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110097"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01787"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414838"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.11.008"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2018-1228"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2017.02.005"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2015.06.020"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2018.08.587"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10803"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000357592"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3406-1"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.15997"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.120.021376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:43:57Z","timestamp":1715600637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.120.021376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":24,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9,7]]}},"alternative-id":["10.1161\/JAHA.120.021376"],"URL":"https:\/\/doi.org\/10.1161\/jaha.120.021376","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"2021-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e021376"}}